TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01553929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training and cognitive activity (EPC group)
Description: The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training (EP group)
Description: The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no physical training and no cognitive activity
Study: NCT02542969

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: MGL-3196
Study: NCT01494207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness counseling
Description: Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
Study: NCT03184740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
Study: NCT02749409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT02592824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutamate infusion
Description: Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
Study: NCT03057886

Intervention type: DEVICE
Intervention: Comparative thermometers to compare with a new device
Description: The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
Study: NCT03720561

Intervention type: DRUG
Intervention: Ibrutinib
Description: Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
Study: NCT01142336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg qHS for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet qHS for 1 year
Study: NCT01704261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to Omarigliptin
Description: Matching placebo to omarigliptin capsule administered orally once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
Study: NCT04550299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical technique combined with a specific choice of the material for the ligament reconstruction
Description: The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical technique combined with a specific choice of the material for the ligament reconstruction
Description: The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical technique combined with a specific choice of the material for the ligament reconstruction
Description: The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical technique combined with a specific choice of the material for the ligament reconstruction
Description: The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
Study: NCT03153670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
Study: NCT00423046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)
Description: Three doses administered intramuscularly at months 0, 1 and 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil ® (Merck & Co. Inc)
Description: Three doses administered intramuscularly at months 0, 2 and 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One dose administered intramuscularly at month 1 to maintain blinding

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose administered intramuscularly at month 2 to maintain blinding
Study: NCT01604785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Ketorolac, Diphenhydramine and Metoclopramide
Study: NCT00879658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03084237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX02
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
Study: NCT01935115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol anesthesia for ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine anesthesia for ECT
Study: NCT01926158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumb
Description: Prefilled syringe of 1 mL denosumab solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for denosumab)
Study: NCT03201991

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Exercise Program
Description: The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
Study: NCT01899911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP)
Description: Infrared and red absorbance measurement
Study: NCT01466361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lower dose
Description: lower dose nicotine lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine higher dose
Description: higher dose nicotine lozenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03568435

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT04056169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose rosuvastatin
Description: rosuvastatin 20 mg once a day for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose rosuvastatin plus ezetimibe
Description: ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Study: NCT00392223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin microspheres
Description: Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline-placebo capsules
Description: minocycline-placebo capsules daily for 8 weeks plus minocycline placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin microspheres-placebo
Description: Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline capsules,
Description: Capsules, PO, 100 mg daily for 8 weeks.
Study: NCT02783911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA
Description: Mineral Trioxide Aggregate grey paste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Sulfate
Description: Ferric Sulfate paste
Study: NCT00872742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance enhanced behavior therapy (AEBT)
Description: Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Description: Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
Study: NCT00747214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD Therapy
Description: DMARD therapy can include methotrexate or other DMARD therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARD Therapy
Description: DMARD therapy can include methotrexate or other DMARD therapy
Study: NCT04155645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233 subcutaneous injection
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233 subcutaneous injection
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233 subcutaneous injection
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive SC dose of placebo injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive SC dose of placebo injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive SC dose of placebo injection.
Study: NCT02339688

Intervention type: OTHER
Group type: OTHER
Intervention: conventional MS rehabilitation
Description: assessment pre and post conventional MS rehabilitation
Study: NCT05928923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP usage 3 months
Study: NCT04748978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy
Description: OPPIum and Myolysis
Study: NCT02080416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
Study: NCT03048786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
Study: NCT01933594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: RMD administered over 4 hours via an intravenous (IV) catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: RMD administered over 4 hours via an intravenous (IV) catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: RMD administered over 4 hours via an intravenous (IV) catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: RMD administered over 4 hours via an intravenous (IV) catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Romidepsin
Description: Placebo for RMD administered over 4 hours via an IV catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Romidepsin
Description: Placebo for RMD administered over 4 hours via an IV catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Romidepsin
Description: Placebo for RMD administered over 4 hours via an IV catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Romidepsin
Description: Placebo for RMD administered over 4 hours via an IV catheter.
Study: NCT04357795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CequaTM (Cyclosporine 0.09%) ophthalmic solution
Description: One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Study: NCT00815152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coping skills intervention training
Description: The strategies will include ways to improve problem solving, communication skills, and managing activities.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: The ususal care at the Preston Robert Tisch Brain Tumor Center
Study: NCT00262119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Medtronic EnRhythm
Description: Pacemaker specific programming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Medtronic EnRhythm
Description: Pacemaker specific programming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Medtronic EnRhythm
Description: Pacemaker specific programming
Study: NCT04334369

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Proclear Single Vision Contact Lenses manufactured by CooperVision
Description: FDA approved single vision contact lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proclear Multifocal Contact Lenses manufactured by CooperVision
Description: FDA Approved Multifocal Contact Lenses
Study: NCT00833755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Study: NCT02754739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
Study: NCT02664675

Intervention type: PROCEDURE
Intervention: Crown lengthening
Description: After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.

Intervention type: PROCEDURE
Intervention: Open Flap Debridement
Description: After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap.

Intervention type: PROCEDURE
Intervention: Open Flap Debridement
Description: After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap.
Study: NCT03687632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: 1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
Study: NCT01612663

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pain relief by Acupuncture needle at non-specific site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture needle

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture needle
Study: NCT03468621

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound closure
Description: Method of wound closure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound closure
Description: Method of wound closure
Study: NCT01832766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: dronabinol 10 mg one capsule by mouth at 8:00 a.m.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: one capsule given by mouth at 8:00 a.m.
Study: NCT04331106

Intervention type: DIAGNOSTIC_TEST
Intervention: Online Questionnaire
Description: Online Questionnaire via SoSci Survey
Study: NCT03356093

Intervention type: OTHER
Intervention: complete questionnaire
Description: Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
Study: NCT05149339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2800 I.U. ml oral drops
Description: (Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3).